| Net Cash Provided by (Used in) Operating Activities |
$17,385 |
USD |
-312% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$19,736 |
USD |
|
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
500,000,000 |
shares |
400% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
109,500,000 |
shares |
9.5% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$2,351 |
USD |
|
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$3,748 |
USD |
296% |
Q3 2025 |
Q3 2025 |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$0 |
USD |
|
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Valuation Allowance |
$412,281 |
USD |
21% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Gross |
$412,281 |
USD |
21% |
Q3 2025 |
Q3 2025 |
| Deferred Income Tax Expense (Benefit) |
$95,533 |
USD |
-21% |
Q1 2025 |
Q1 2025 |
| Additional Paid in Capital |
$11,917 |
USD |
|
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$0 |
USD |
|
Q3 2025 |
Q3 2025 |
| Interest Expense |
$8,280 |
USD |
10% |
Q1 2025 |
Q1 2025 |